GILD
Another liver-data flex
Gilead kicked out fresh Phase 3 results for Livdelzi, also known as seladelpar, and the headline is pretty simple: the drug helped more patients with primary biliary cholangitis hit composite ALP normalization than placebo after 52 weeks.
ALP might sound like the kind of acronym your accountant invents, but in this corner of medicine it matters. It’s a key liver marker tied to disease progression, so when a treatment moves it the right way, investors perk up like someone just mentioned a surprise dividend.
Why this matters
This isn’t a moonshot biotech roulette spin. It’s a data point that can help Gilead keep stitching together a liver franchise that looks more and more like a real business, not just a science project.
What to watch:
- whether Gilead frames this as supporting broader commercial uptake
- whether the data strengthens Livdelzi’s place in PBC treatment
- whether investors start treating the asset as a sturdier long-term contributor
The bigger picture
Gilead has been busy padding its pipeline with wins, and this is the kind of clean clinical readout that helps the market stay interested. Not flashy enough for a meme-stock victory lap, but in biotech, “statistically significant” is basically the closest thing to a mic drop.
Big picture: more positive liver data gives Gilead another brick in the wall — and Wall Street likes walls that keep growing.